| Renal Impairment Pharmacokinetics (PK) Trial of Afabicin (NCT07758608) | Debiopharm International SA | 2026-08-01 |
| A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (NCT06930625) | Debiopharm International SA | 2025-11-26 |
| A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults (NCT07035769) | Debiopharm International SA | 2025-06-18 |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) (NCT06969430) | Debiopharm International SA | 2025-05-30 |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer (NCT06395753) | Debiopharm International SA | 2024-05-23 |
| Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (NCT05815160) | Debiopharm International SA | 2023-05-02 |
| Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (NCT05147350) | Debiopharm International SA | 2022-08-09 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (NCT05364944) | Debiopharm International SA | 2022-05-18 |
| Study of RP-6306 With Gemcitabine in Advanced Solid Tumors (NCT05147272) | Debiopharm International SA | 2021-12-16 |
| A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (NCT05109975) | Debiopharm International SA | 2021-11-05 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants (NCT04962724) | Debiopharm International SA | 2021-08-02 |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (NCT04855656) | Debiopharm International SA | 2021-04-30 |
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors (NCT03968653) | Debiopharm International SA | 2019-07-30 |
| Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (NCT04122625) | Debiopharm International SA | 2019-04-26 |
| Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) (NCT03834220) | Debiopharm International SA | 2019-03-22 |
| Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus (NCT03723551) | Debiopharm International SA | 2019-02-20 |
| A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy (NCT03270176) | Debiopharm International SA | 2017-10-10 |